A clinical formulation indicated for Cholesterol. Treatment assists with the regulation of lipid metabolism to decrease elevated triglyceride levels in the bloodstream.
Indicated to address dangerous triglyceride levels to mitigate pancreatitis risk and alleviate arterial plaque buildup to support long-term heart and cardiovascular stability.
Mechanism of Action
Gemfibrozil stimulates an enzyme that helps break down fats in the blood. It reduces the liver's production of triglycerides and VLDL, while boosting the production of 'good' HDL cholesterol to improve the overall lipid profile.
Route of Administration
Oral
Onset Time
Steady state in 1–2 weeks
Duration
12–24 hours
Contraindications
Severe kidney disease, Active liver disease, Gallbladder disease, Concurrent simvastatin use, Concurrent repaglinide use
Severe Adverse Events
Rhabdomyolysis (muscle death), Liver failure, Severe pancreatitis, Gallstones, Blood count changes, Severe allergic reactions
Information for Gemfibrozil is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
